Pulse Biosciences Relocates Executive Offices to Miami

Ticker: PLSE · Form: 8-K · Filed: Nov 26, 2024 · CIK: 1625101

Pulse Biosciences, Inc. 8-K Filing Summary
FieldDetail
CompanyPulse Biosciences, Inc. (PLSE)
Form Type8-K
Filed DateNov 26, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-action, relocation

TL;DR

Pulse Biosciences HQ moving from CA to FL, effective Nov 26, 2024.

AI Summary

On November 26, 2024, Pulse Biosciences, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices from Hayward, California to Miami, Florida. The new address is 601 Brickell Key Drive, Suite 1080, Miami, Florida 33131.

Why It Matters

This relocation may signal strategic shifts or operational changes for Pulse Biosciences, potentially impacting its business operations and investor relations.

Risk Assessment

Risk Level: low — The filing is a routine administrative update regarding the company's principal executive office location.

Key Players & Entities

  • Pulse Biosciences, Inc. (company) — Registrant
  • November 26, 2024 (date) — Date of Report
  • Miami, Florida (location) — New Principal Executive Offices
  • Hayward, California (location) — Former Principal Executive Offices
  • 601 Brickell Key Drive, Suite 1080 (address) — New Principal Executive Offices Address

FAQ

What is the new principal executive office address for Pulse Biosciences, Inc.?

The new principal executive office address for Pulse Biosciences, Inc. is 601 Brickell Key Drive, Suite 1080, Miami, Florida 33131.

When was this change of address reported?

This change of address was reported on November 26, 2024.

What was the previous location of Pulse Biosciences, Inc.'s principal executive offices?

The previous location of Pulse Biosciences, Inc.'s principal executive offices was in Hayward, California.

Is this a change in the company's legal domicile?

No, the filing indicates the company is incorporated in Delaware and the change pertains to its principal executive offices.

Does this filing indicate any operational changes beyond the office relocation?

The filing specifically reports the change in principal executive offices and does not detail other operational changes.

Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-11-26 12:36:49

Key Financial Figures

  • $0.001 — nge on Which Registered Common stock , $0.001 par value per share PLSE The Nasdaq

Filing Documents

01

Item 7.01 Regulation FD Disclosure. The controlling stockholder and Co-Chairman of Pulse Biosciences, Inc. (the "Company"), Robert W. Duggan, has informed management that he is evaluating one or more potential market purchases of Company common stock, and the Company has cleared these pursuant to its Insider Trading Policy, giving Mr. Duggan through the end of December 10, 2024 to purchase, in his sole discretion, up to 500,000 shares of Company common stock. The information contained in Item 7.01 to this Current Report on Form 8-K shall not be deemed " filed " for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act " ), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly stated otherwise. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: November 26, 2024 By: /s/ Burke T. Barrett Burke T. Barrett President and Chief Executive Officer (Principal Executive and Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.